Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression
Brain Sciences · 13.01.2023 · 13 (1) · 142
DOI: 10.3390/brainsci13010142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Sciences, online erschienen am 13.01.2023. Verfasst von Maria Gałuszko-Węgielnik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Gdansk, Poland.
Themen: Depression
Abstract (Originalsprache)
Psychotic treatment-resistant depression is a complex and challenging manifestation of mood disorders in the clinical setting. Psychotic depression is a subtype of major depressive disorder characterized by mood-consistent hallucinations and/or delusions. Psychotic depression is often underdiagnosed and undertreated. Ketamine appears to have rapid and potent antidepressant effects in clinical studies, and the Federal Drug Agency approved the use of ketamine enantiomer esketamine-nasal spray for treatment-resistant depression pharmacotherapy in 2019. This study aimed to assess the usage of ketamine for major depressive disorder with psychotic features as an add-on treatment to the standard of care. Here we present four inpatients suffering from treatment-resistant depression with psychotic features, including one with severe suicidal crisis, all treated with 0.5 mg/kg intravenous infusion of ketamine. Subsequent monitoring revealed no exacerbation of psychotic symptoms in short and long-term observation, while stable remission was observed in all cases with imminent antisuicidal effect. Results suggest ketamine may benefit individuals with treatment-resistant depression with psychotic features.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland.
ORCID-Profile: Maria Gałuszko-Węgielnik, Zuzanna Chmielewska, Wiesław J Cubała
Förderung
- Medical University of Gdansk, Poland
Zitieren
APA
Gałuszko-Węgielnik, M., Chmielewska, Z., Jakuszkowiak-Wojten, K., Wiglusz, M. S., & Cubała, W. J. (2023). Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression. Brain Sciences, 13(1), 142. https://doi.org/10.3390/brainsci13010142
Vancouver
Gałuszko-Węgielnik M, Chmielewska Z, Jakuszkowiak-Wojten K, Wiglusz MS, Cubała WJ. Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression. Brain Sciences. 2023;13(1):142. doi:10.3390/brainsci13010142
BibTeX
@article{GauszkoWgielnik2023,
author = {Gałuszko-Węgielnik, Maria and Chmielewska, Zuzanna and Jakuszkowiak-Wojten, Katarzyna and Wiglusz, Mariusz S and Cubała, Wiesław J},
title = {Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression},
journal = {Brain Sciences},
year = {2023},
volume = {13},
number = {1},
pages = {142},
doi = {10.3390/brainsci13010142}
}
EUVIMED